Patents by Inventor David S. Alberts

David S. Alberts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9320764
    Abstract: A method for enhancing production of Vitamin D within a person's skin includes a source of Vitamin D, a sunlight exposure indicator, and a sunscreen. Vitamin D, for example, cod liver oil, is applied to the skin topically via a patch or towlette, or ingested orally. The exposure indicator is worn by the user and changes its state to indicate that the person has been exposed to sunlight for a predetermined period of time. The user preferably waits a sufficient time for the Vitamin D to be absorbed into the skin, and then exposes his or her skin to direct sunlight, and monitors the exposure indicator to determine if it has changed state. The user applies the sunscreen to the user's skin after the exposure indicator changes state.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: April 26, 2016
    Assignee: TOPICAL TECHNOLOGIES, INC.
    Inventor: David S. Alberts
  • Publication number: 20110166108
    Abstract: The present invention relates to new uses of thermally stable, crystalline S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by radiation treatment. In particular, the invention provides a method for treating or preventing xerostomia associated with the administration of radiation treatment of head and neck cancer.
    Type: Application
    Filed: December 8, 2010
    Publication date: July 7, 2011
    Inventors: Martin STOGNIEW, David S. ALBERTS, Edward H. KAPLAN
  • Publication number: 20110123469
    Abstract: A method for enhancing production of Vitamin D within a person's skin includes a source of Vitamin D, a sunlight exposure indicator, and a sunscreen. Vitamin D, for example, cod liver oil, is applied to the skin topically via a patch or towlette, or ingested orally. The exposure indicator is worn by the user and changes its state to indicate that the person has been exposed to sunlight for a predetermined period of time. The user preferably waits a sufficient time for the Vitamin D to be absorbed into the skin, and then exposes his or her skin to direct sunlight, and monitors the exposure indicator to determine if it has changed state. The user applies the sunscreen to the user's skin after the exposure indicator changes state.
    Type: Application
    Filed: February 1, 2011
    Publication date: May 26, 2011
    Applicant: TOPICAL TECHNOLOGIES, INC.
    Inventor: David S. Alberts
  • Publication number: 20100226946
    Abstract: A kit for enhancing production of Vitamin D within a person's skin includes a source of Vitamin D, a sunlight exposure indicator, and a sunscreen. Vitamin D, for example, cod liver oil, is applied to the skin topically via a patch or towlette, or ingested orally. The exposure indicator is worn by the user and changes its state to indicate that the person has been exposed to sunlight for a predetermined period of time. The user preferably waits a sufficient time for the Vitamin D to be absorbed into the skin, and then exposes his or her skin to direct sunlight, and monitors the exposure indicator to determine if it has changed state. The user applies the sunscreen to the user's skin after the exposure indicator changes state.
    Type: Application
    Filed: March 4, 2009
    Publication date: September 9, 2010
    Applicant: TOPICAL TECHNOLOGIES, INC.
    Inventor: David S. Alberts
  • Publication number: 20080153891
    Abstract: The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of treating cancer using the synergistic combinations.
    Type: Application
    Filed: December 6, 2007
    Publication date: June 26, 2008
    Applicant: The Arizona Board of Regents
    Inventors: Robert T. DORR, David S. Alberts, Evan M. Hersh
  • Publication number: 20080146653
    Abstract: The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of treating cancer using the synergistic combinations.
    Type: Application
    Filed: December 6, 2007
    Publication date: June 19, 2008
    Applicant: The Arizona Board of Regents
    Inventors: Robert T. DORR, David S. Alberts, Evan M. Hersh
  • Patent number: 7105575
    Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: September 12, 2006
    Assignee: Medimmune Oncology Inc.
    Inventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
  • Publication number: 20040106588
    Abstract: A method for treating pre-cancerous conditions including non-cancerous lesions and non-invasive carcinoma insitu, in cutaneous, and muco-cutaneous regions of the body includes topical application of combinations containing alpha-DFMO and an anti-inflammatory agent selected from the group comprising a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, or a combination thereof. The conditions which may be topically treated with the combination of the present invention include actinic keratoses, vulvar neoplasia, and pre-cancerous conditions of the lip, nostrils, nails, and anus. In one case, the topical steroid triamcinolone is combined with the alpha-DFMO. In a second case, the topical non-steroid anti-inflammatory diclofenac is combined with the alpha-DFMO. In a third instance, both triamcinolone and diclofenac are combined with the alpha-DFMO.
    Type: Application
    Filed: September 3, 2003
    Publication date: June 3, 2004
    Inventors: David S. Alberts, Robert T. Dorr
  • Publication number: 20040043975
    Abstract: Topical alpha-DFMO is mixed with a hydrophillic ointment base, along with at least one additional active drug, for treating actinic keratoses by topical application to human skin tissues. In one case, the topical steroid triamcinolone is combined with the alpha-DFMO. In a second case, the topical non-steroid anti-inflammatory diclofenac is combined with the alpha-DFMO. In a third instance, both triamcinolone and diclofenac are combined with the alpha-DFMO. In all such instances, topical application of such combinations was found to inhibit squamous cell cancer, and the combined effect of such components, when selected in appropriate proportions, in inhibiting squamous cell cancer cells is significantly greater than the effectiveness of each such component by itself.
    Type: Application
    Filed: September 3, 2003
    Publication date: March 4, 2004
    Applicant: TOPICAL TECHNOLOGIES, INC.
    Inventors: David S. Alberts, Robert T. Dorr
  • Publication number: 20030129208
    Abstract: Topical alpha-DFMO is mixed with a hydrophillic ointment base, along with at least one additional active drug, for treating actinic keratoses by topical application to human skin tissues. In one case, the topical steroid triamcinolone is combined with the alpha-DFMO. In a second case, the topical non-steroid anti-inflammatory diclofenac is combined with the alpha-DFMO. In a third instance, both triamcinolone and diclofenac are combined with the alpha-DFMO. In all such instances, topical application of such combinations was found to inhibit squamous cell cancer, and the combined effect of such components, when selected in appropriate proportions, in inhibiting squamous cell cancer cells is significantly greater than the effectiveness of each such component by itself.
    Type: Application
    Filed: January 7, 2002
    Publication date: July 10, 2003
    Inventors: David S. Alberts, Robert T. Dorr
  • Patent number: 6586476
    Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: July 1, 2003
    Assignee: MedImmune Oncology, Inc.
    Inventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
  • Publication number: 20020132795
    Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.
    Type: Application
    Filed: May 3, 2002
    Publication date: September 19, 2002
    Applicant: U.S. Bioscience, Inc.
    Inventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
  • Patent number: 6204064
    Abstract: A method is disclosed for quantitatively measuring the progression of a lesion toward malignant disease by digitizing images of clinical samples of biopsied lesions using a microphotometer that includes a video camera, and a computer that includes a video frame capture board. The digitized image is analyzed to locate the borders of cell nuclei within the captured video image, and one or more chromatin texture features within such nuclei are processed by the computer to arrive at a numerical value. This numerical value is compared to a monotonic progression curve that has been previously established by using the same procedure on known clinical samples ranging from normal tissue to malignant disease. The method can also be used to test the efficacy of chemopreventive drugs and treatments.
    Type: Grant
    Filed: January 30, 1999
    Date of Patent: March 20, 2001
    Inventors: David S. Alberts, Peter H. Bartels
  • Patent number: 6060083
    Abstract: A method for treating palmar-plantar erythrodysethesia syndrome includes applying to affected areas a therapeutically effective amount of a dimethyl sulfoxide solution.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: May 9, 2000
    Assignee: Topical Technologies, Inc.
    Inventors: Robert T. Dorr, David S. Alberts
  • Patent number: 5994409
    Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.
    Type: Grant
    Filed: December 9, 1997
    Date of Patent: November 30, 1999
    Assignees: U.S. Bioscience, Inc., The Arizona Board of Regents on behalf of the University of Arizona
    Inventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
  • Patent number: 5985302
    Abstract: Methods, compositions and a kit for deactivating spills or leaks of HIV infected blood or anticancer drugs by applying to the leak or spill an aqueous solution containing calcium hypochlorite or sodium hypochlorite as the active ingredient. In order to thicken the aqueous solution and thus keep it from spreading beyond its intended area of application, the solution of calcium hypochlorite contains methylcellulose. In addition to chemically deactivating the active anticancer drug, the solution of the invention also effectively decolorizes it, thus preventing permanent stains on any surface or fabric with which the anticancer drug comes into contact.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: November 16, 1999
    Assignee: Supergen, Inc.
    Inventors: Robert T. Dorr, David S. Alberts
  • Patent number: 5851537
    Abstract: A salve includes a water-miscible, hydrophilic cream vehicle, 1-22% by weight a-DFMO, and no absorption enhancer. The salve is preferably contained in an ointment tube permanently sealed at one end to preclude exposure to light and air. The salve is applied as a preventative in an appropriate amount twice daily to skin exposed to actinic radiation. An initial application of a salve including 10% by weight A-DFMO is preferred to minimize the risk of skin irritation without compromising the therapeutic value of the salve. The salve shows no systemic uptake, thereby eliminating systemic toxicities that result from other techniques for administering the drug.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: December 22, 1998
    Assignee: Cancer Technologies, Inc.
    Inventors: David S. Alberts, Robert T. Dorr
  • Patent number: 5811113
    Abstract: Methods, compositions and a kit for deactivating spills or leaks of HIV infected blood or anticancer drugs by applying to the leak or spill an aqueous solution containing calcium hypochlorite or sodium hypochlorite as the active ingredient. In order to thicken the aqueous solution and thus keep it from spreading beyond its intended area of application, the solution of calcium hypochlorite contains methylcellulose. In addition to chemically deactivating the active anticancer drug, the solution of the invention also effectively decolorizes it, thus preventing permanent stains on any surface or fabric with which the anticancer drug comes into contact.
    Type: Grant
    Filed: November 6, 1992
    Date of Patent: September 22, 1998
    Assignee: Cancer Technologies, Inc.
    Inventors: Robert T. Dorr, David S. Alberts
  • Patent number: 5635506
    Abstract: This invention relates to a compound useful for the treatment of tumors having the formula: ##STR1##
    Type: Grant
    Filed: November 18, 1993
    Date of Patent: June 3, 1997
    Assignee: Research Corporation Technologies, Inc.
    Inventors: David S. Alberts, Robert T. Dorr, William A. Remers, Salah M. Sami
  • Patent number: 5246955
    Abstract: New cytotoxic quionones, designated amamitosenes and iminoazamitosenes are found to have significant activity against ovarian tumors, colon cancer, myecloma and the like neoplastic diseases.Pharmaceutical preparations and therapeutic regimens utilizing azamitosenes and iminoazamitosenes and their pharmaceutically active derivatives are disclosed.
    Type: Grant
    Filed: February 13, 1992
    Date of Patent: September 21, 1993
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Edward B. Skibo, Imadul Islam, David S. Alberts